Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancy 1MDS 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 52Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 42Busulfan 37Azacitidine 34Whole-Body Irradiation 31Mycophenolic Acid 29Cytarabine 28Cyclosporine 28Tacrolimus 27Methotrexate 25Filgrastim 21Decitabine 20Radiotherapy 19Antilymphocyte Serum 19Methylprednisolone 14Melphalan 13Etoposide 13fludarabine 10Cyclosporins 9Idarubicin 8Granulocyte Colony-Stimulating Factor 8Flow Cytometry 8sargramostim 7Psychiatric Rehabilitation 7Cord Blood Stem Cell Transplantation 7merphos 6aldesleukin 6Topotecan 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Chronic × eprenetapopt × Clear all
NCT03072043 2022-01-24

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
55 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡